



Corporate

Ind-Swift Limited

781, Industrial Area, Phase-II,
Chandigarh - 160 002 INDIA
Ph. : 0172- 4680800, 2638781
Fax : 0172-2652242
E-mail : corporate@indswift.com
CIN No. : L24230CH1986PLC006897

Ref.:ISL:CH:2025

Date: 20th February, 2025

The President,
Corporate Relationship Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

The Vice President,
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor,
Plot No. C/2, G-Block,
Bandra Kurla Complex, Bandra (E),
Mumbai 400 051

BSE Scrip Code: 524652

NSE Symbol: INDSWFTLTD

SUB: INTIMATION UNDER REGULATION 30 OF THE SEBI (LISTING OBLIGATION AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015- APPOINTMENT OF SENIOR MANAGEMENT PERSONNEL

Dear Sir/Ma'am,

Pursuant to Regulation 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that Mr. Anil Agrawal, has been appointed as "Chief Operating Officer (COO)" of the Company w.e.f. 20th February, 2025.

The information required to be disclosed under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are enclosed as Annexure I.

We request you to take the above information on record.

Thanking you,

For IND SWIFT LIMITED

**PUNEET KHURANA
COMPANY SECRETARY &
COMPLIANCE OFFICER**



Corporate

Ind-Swift Limited

781, Industrial Area, Phase-II,
Chandigarh - 160 002 INDIA
Ph. : 0172- 4680800, 2638781
Fax : 0172-2652242
E-mail : corporate@indswift.com
CIN No. : L24230CH1986PLC006897

(Annexure I)

Name of the Senior Management Personnel	Mr. Anil Agrawal
Date of Appointment	20 th February, 2025
Reason for change	Appointment w.e.f 20.02.2025
Brief Profile	<p>Mr. Anil Agrawal is a seasoned professional with a Bachelor of Pharmacy degree from Devi Ahilya Vishwavidyalaya, Indore, MP. He has a rich and diverse experience of more than 25 years in leading pharmaceutical operations at some of the most reputed organizations in the industry. His distinguished career includes leadership roles at Ranbaxy Laboratories Ltd, Dr. Reddy's Laboratories Ltd, Glenmark Pharmaceuticals Ltd, GlaxoSmithKline Pharmaceuticals Ltd, Zydus Cadila Healthcare Ltd, Alembic Pharmaceuticals Ltd, Par Formulations, and Sun Pharmaceutical Industries Ltd.</p> <p>His extensive expertise in pharmaceutical manufacturing, operational efficiencies, and business transformation will be invaluable in elevating our formulation business to new heights.</p>
Disclosure of Relationship between Directors	NA